Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

About this update from Esperion Therapeutics, Inc.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics , Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. >>> CLICK HERE To Learn More. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( [email protected] ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-espr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com . CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn View source version on businesswire.com: https://www.businesswire.com/news/home/20260617386094/en/

View stock analysis, news, and events for Esperion Therapeutics, Inc.